This is helping my immune system, energy levels, better for my organs
Originally developed to help manage Type 2 diabetes, semaglutide is now being used for weight loss, and many women are finding it to be a game-changer
Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma
No agitar
GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg) for once-weekly, subcutaneous (SC) administration for weight reduction and long-term maintenance
This should include: Comprehensive medication review : Documenting all prescribed medications, over-the-counter products, and supplements to identify potential interactions, particularly noting fluoxetine's strong CYP2D6 inhibition Mental health evaluation : Assessing depression severity, suicide risk, and treatment response to fluoxetine Weight and metabolic parameters : Recording baseline weight, BMI, waist circumference, blood pressure, and relevant blood tests (HbA1c, lipid profile, liver function) Renal function and electrolytes : Particularly sodium levels, given the risk of SSRI-induced hyponatraemia Cardiovascular assessment : Particularly important given semaglutide's potential effects on heart rate Gastrointestinal and gallbladder history : Identifying pre-existing conditions that might be exacerbated Ophthalmological assessment : For patients with diabetes, as rapid improvement in glycaemic control may worsen diabetic retinopathy Ongoing monitoring should occur at regular intervals, typically: Monthly initially : During Wegovy dose escalation (following the standard titration schedule from 0.25 mg to 2.4 mg over 1620 weeks) Every 36 months : Once stable doses are achieved, monitoring weight, mental health status, side effects, and treatment adherence As clinically indicated : More frequent review if concerns arise Dose adjustments may be necessary based on individual response
